SPR-206 is a small molecule commercialized by Everest Medicines, with a leading Phase I program in Acinetobacter Infections. According to Globaldata, it is involved in 5 clinical trials, of which 4 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of SPR-206’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for SPR-206 is expected to reach an annual total of $66 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

SPR-206 Overview

SPR-206 is under develoment for the treatment of gram-negative bacterial infections including Acinetobacter baumanii and Pseudomonas aeruginosa and Carbapenem-resistant Enterobacteriaceae infection, complicated urinary tract infections, hospital acquired pneumonia, ventilator associated pneumonia and bloodstream infections. The drug candidate is a polymyxin derivative. It is administered through intravenous route. The drug candidate acts by targeting cell membrane protein lipopolysaccharide.

Everest Medicines Overview

Everest Medicines is a biopharmaceutical company that licenses, develops and commercializes medicines for the treatment of cancer, autoimmune, cardiorenal and infectious diseases. It is investigating Sacituzumab govitecan, an antibody-drug conjugate targeting metastatic triple-negative breast cancer (mTNBC), metastatic urothelial cancer (mUc), non-small cell lung cancer (NSCLC) and other oncology indications; and FGF401 for hepatocellular carcinoma. The company is evaluating Etrasimod to treat ulcerative colitis and other autoimmune diseases; Nefecon for IgA nephropathy; Ralinepag against pulmonary arterial hypertension (PAH). Everest Medicines is also developing drugs for community-acquired bacterial pneumonia (CABP), complicated urinary tract infection (cUTi) and other infectious diseases. It works in partnership with Immunomedics, Novartis, Arena Pharmaceuticals and other companies to develop its products. Everest Medicines is headquartered in Shanghai, China.

The company reported revenues of (Renminbi) CNY12.8 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of CNY0.1 million in FY2021. The operating loss of the company was CNY256.8 million in FY2022, compared to an operating loss of CNY1,026.3 million in FY2021. The net loss of the company was CNY247.3 million in FY2022, compared to a net loss of CNY1,008.7 million in FY2021.

For a complete picture of SPR-206’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.